Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

In a recent comparative network meta-analysis, icotrokinra (ICO) demonstrated efficacy for attaining completely clear skin, matching injectable interleukin (IL)-23 inhibitors and outperforming approved advanced oral medications in patients with 

, was titled ‘Comparative analysis of icotrokinra and approved advanced treatments for achievement of completely clear skin in patients with moderate-to-severe psoriasis: A systematic literature review and network meta-analysis.’ The data add to the growing number of studies pointing to the efficacy and safety of icotrokinra as a possible psoriasis therapy option.

This data was authored by such investigators as April W. Armstrong, MD, MPH, professor and chief of dermatology at UCLA. Armstrong and colleagues noted completely clear skin had recently become considered an attainable objective of psoriasis treatment rather than an aspirational objective. They also pointed to recent web-based survey findings from around 400 patients with psoriasis and 200 healthcare professionals, all of which suggested the dominant driver of disease burden was visible symptoms.

Both patients and clinician respondents also suggested a strong preference for oral systemic medications, as opposed to topicals or injectables. Armstrong and coauthors suggested these data underscore the need for efficacy combined with convenient administration.

ICO, an investigational oral peptide, was developed to selectively bind the IL-23 receptor and inhibit IL-23–mediated signaling. Investigation of the drug’s use in moderate-to-severe plaque psoriasis has been done in several phase 3 clinical trials: LEAD, ADVANCE 1, and ADVANCE 2. Robust efficacy, as evidenced by significantly higher rates of completely clear skin compared with placebo and ICO’s performance versus deucravacitinib, was suggested at the time these data were released.

A limited level of availability of head-to-head randomized trials (RCTs) in psoriasis led to Armstrong and colleagues’ systematic literature review and network meta-analysis (NMA), with the investigators seeking to contextualize ICO’s efficacy relative to approved advanced treatments. It was performed in March 2025, with the team including RCTs in adults assessing biologics and advanced oral agents at approved doses. For consistency with prior analyses, they treated Static Physician's Global Assessment (sPGA) 0 and PGA 0 outcomes as equivalent to Investigator's Global Assessment (IGA) 0.

A week 16 timepoint was used in this NMA with the aim of maximizing comparability across research. Random-effects Bayesian models were utilized as well, to account for between-trial heterogeneity. Baseline adjustment of risk was not applied by Armstrong et al due to minimal placebo response rates. The findings were interpreted via a predefined probabilistic framework, as the investigators sought to classify whether ICO was superior, favored, or comparable to other drugs.

Overall, the study suggested ICO therapy led to rates of completely clear skin comparable to injectable IL-23 inhibitors. It was also shown to be superior to other advanced oral treatments in this study, with results being consistent across both Psoriasis Area and Severity Index (PASI) 100 and IGA 0 endpoints. Armstrong and coauthors’ data indicate ICO may provide those on the drug with a highly effective, once-daily oral option. In future research, further exploration may be needed to assess long-term comparative outcomes.

These data, coupled with findings on icotrokinra previously reported by 

, add to the growing body of evidence supporting icotrokinra’s potential approval by the US Food and Drug Administration for psoriasis.

Armstrong A, et al. Comparative analysis of icotrokinra and approved advanced treatments for achievement of completely clear skin in patients with moderate-to-severe psoriasis: A systematic literature review and network meta-analysis. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29.

Soung, J, et al. Maintenance of Response with Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Psoriasis : Randomized Treatment Withdrawal in Adults (weeks 24-52) and Continuous Treatment in Adolescents (Through Week 52) From the Phase 3, ICONIC-LEAD Trial. Late-breaking research oral presentation (Presentation #D1T01.2B) at the European Academy of Dermatology and Venereology Congress (EADV). September 2025. Accessed January 27, 2026.

Stein Gold L, et al. Icotrokinra Demonstrated Superior Responses Compared with Placebo and Deucravacitinib in the Treatment of Moderate-to-Severe Plaque Psoriasis : Results Through Week 24 of the Phase 3 ICONIC-ADVANCE 1&2 Studies. Oral presentation (Presentation FC01.1G) at the European Academy of Dermatology and Venereology Congress (EADV). September 2025. Accessed January 27, 2026.

Bissonnette R, et al. Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23–Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-blind, Placebo-Controlled ICONIC-LEAD Trial. Late-breaking research presentation (Abstract #66708) at the American Academy of Dermatology (AAD) 2024 Annual Meeting. March 2025. Accessed January 27, 2026.

Articles

Icotrokinra (ICO), an investigational oral peptide, has shown promising results in achieving completely clear skin in patients with moderate-to-severe psoriasis. It matches the efficacy of injectable IL-23 inhibitors and surpasses other advanced oral treatments. The study, presented at the 2026 Maui Derm Hawaii conference, highlights ICO's potential as a convenient, once-daily oral therapy. The network meta-analysis, led by Dr. April W. Armstrong, utilized Bayesian models to compare ICO with other treatments, emphasizing its robust efficacy and potential for FDA approval.

At the 2026 Maui Derm Hawaii meeting, recent data on icotrokinra’s use in patients with psoriasis were highlighted.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Icotrokinra Data at Maui Derm 2026 Reaffirm Efficacy in Psoriasis

Discussing GLP-1s, New Dermatology Therapies in 2026, With Neal Bhatia, MD

 featured a session titled ‘New Drugs and Therapies in 2026,’ presented by 2 notable leaders in the dermatology field: Neal Bhatia, MD, and Ted Rosen, MD.

Bhatia, known for his role as the director of clinical dermatology at Therapeutics Clinical Research, spoke with the 

 team in an interview regarding some of the most notable takeaways from his and Rosen’s discussion of newer therapies

“We do what was approved in the last 3 months, what's going to be approved in the next 3 months, and then what's in the pipeline,” Bhatia explained.

The pair of speakers had focused their attention on such therapies as intralesional skin cancer treatments, touching briefly on VP-315. BP-315 is an experimental, first-in-class, injectable oncolytic peptide treatment developed for non-surgical skin cancer management. It primarily is used in basal cell carcinoma (BCC). Additionally, Bhatia noted several updates on topical Janus Kinase (JAK)-inhibitor use and treating chronic hand eczema.

“The pipeline is very rich for some of those systemic agents,” Bhatia said. “Part of the problem is the pipeline is very poor for topical agents. So we're trying to expand the uses of many of the topicals we have, and that was a lot of our discussion.”

Atopic dermatitis was described by Bhatia as having no shortage of drugs in the pipeline. However, he points to the lack of randomized clinical trials in other inflammatory skin diseases, given the smaller patient populations. In particular, he pointed to patients suffering from hives and urticaria. Chronic spontaneous urticaria (CSU) has replicable data.

 approved medications for urticaria have to go under the category of CSU, Bhatia noted. Omalizumab was FDA-approved in years prior, dupilumab received an approval as well, and remibrutinib is now approved for CSU.

 He later pointed to developments in GLP-1 agonists in dermatology as another new development.

“We did mention the GLP-1s as well,” Bhatia noted. “...There's a lot of good data on reduction of tumor necrosis factor, interleukin-17, some of the other interleukins, but it's also it's big on insulin resistance. You can reduce insulin resistance, you can improve a lot of the inflammatory outcomes as well.”

One should not use GLP-1s alone, Bhatia explained, as it is not an individual cure for any single dermatologic disease. However, adding such treatments on to existing therapy should be considered. As an exmaple, he pointed to weight improvements among patients with psoriasis and hidradenitis suppurativa (HS) leading to wound healing improvements and quality of life improvements.

The quotes included in this interview summary were edited for clarity.

Bhatia has reported serving as an advisor, consultant, and investigator for AbbVie, Almirall, Arcutis Biotherapeutics, Beiersdorf, Biofrontera, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant Sciences, EPI Health, Ferndale, Galderma, Incyte, ISDIN, Johnson & Johnson, La Roche-Posay, LEO Pharma, Lilly, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, and Verrica Pharmaceuticals.

Rosen T, Bhatia N. New Drugs and Therapies in 2026. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29.

Novartis Pharma AG. Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU). GlobeNewswire News Room. Published September 30, 2025. Accessed January 27, 2026. 

https://www.globenewswire.com/news-release/2025/09/30/3159065/0/en/Novartis-receives-FDA-approval-for-Rhapsido-remibrutinib-the-only-oral-targeted-BTKi-treatment-for-chronic-spontaneous-urticaria-CSU.html

Videos

Neal Bhatia, MD, speaks in this interview regarding his discussion at Maui Derm Hawaii of new and emerging therapies in dermatology.

Robert Negrin, MD, is president of the American Society of Hematology and a professor of medicine at Stanford University. 

Looking Ahead to ASH’s 68th Meeting, With President Robert Negrin, MD

 recently wrapped its 67th Annual Meeting and Exposition in Orlando, Florida, with > 8,200 abstracts accepted and > 1,100 oral presentations, exemplifying the expansive nature of the 

“The science was spectacular,” said Robert Negrin, MD, newly elected president of ASH and professor of medicine at Stanford University, in an interview with 

That goes without saying. I think that's something that happens every year, but I would say that the late-breaking abstract session was probably the best session I've ever attended. Every paper was practice-changing or groundbreaking.

At the 67th ASH meeting, investigators highlighted in vivo CAR T therapies, next-generation autologous and allogeneic CAR T platforms, and novel bispecific antibodies, chemotherapy combinations improving outcomes in myeloma and other hematologic diseases. Key data included the Phase 2 iMMagine‑1 trial of anitocabtagene autoleucel, the phase 3 MajesTEC‑3 trial of teclistamab with anti‑CD38 therapy, a phase 2 cevostamab post-CAR T study, early Durga‑1 results on AZD0120, extended ELARA follow-up on tisagenlecleucel, and updates from CARTITUDE‑4 and the COBRA trial.

These findings reinforce a rapidly evolving hematology landscape, demonstrating the impact of CAR T therapies, next-generation platforms, and bispecific antibody combinations can deliver deeper, more durable responses in myeloma and lymphoma. They signal potential shifts in standard care, expand treatment options for relapsed or refractory patients, and highlight the promise of personalized, multi-antigen strategies to improve outcomes across hematologic diseases.

Negrin has been involved in the organization since he attended his first meeting as a fellow in the 1990s. In his 33 years as a member, he served as the inaugural editor-in-chief of 

, as an ad hoc member of the Executive Committee, and as chair of the Scientific Committee on Transplant Biology and Cellular Therapies.

“Many people describe ASH as their scientific family, and that is something the leadership should take great pride in. For me personally, it’s been an opportunity to contribute through various committees, journals, and now the executive committee,” remarked Negrin. “It is vital that we demonstrate to our community that ASH will continue to enrich opportunities and experiences for its members worldwide.”

Over his career, Negrin’s research has focused on understanding and improving the biology of immune responses after bone marrow and stem cell transplants, including the balance between graft‑versus‑host disease and graft‑versus‑tumor effects using animal models and clinical studies. Additionally, he has been involved in investigating how specific immune cell populations influence graft outcomes and immunotherapy, including work on cytotoxic T cells and regulatory T cells to improve transplant success and reduce complications.

Looking ahead, the 68th Annual Meeting and Exposition will take place December 12–15, 2026, in New Orleans, Louisiana.

“I’m also really excited about going to New Orleans. It’s a fantastic city, and the meeting will be buzzing with activity. There are so many highlights in the annual program, and I can’t give all the secrets away, you have to be there to experience it. But most importantly, the meeting reinforces a sense of community, which I think is critical.”

Editor’s note: Negrin reports relevant disclosures with BioEclipse Therapeutics, Biorasi, Amgen, and others.

Highlights of ASH in North America - Hematology.org. Hematology.org. Published 2026. Accessed January 27, 2026. 

https://www.hematology.org/meetings/highlights-of-ash-in-north-america

Robert Negrin MD Begins Term as 2026 ASH President - Hematology.org. Hematology.org. Published 2026. Accessed January 27, 2026. https://www.hematology.org/newsroom/press-releases/2026/robert-negrin-md-begins-term-as-2026-ash-president
‌Negrin Lab. Blood & Marrow Transplantation& Cellular Therapy Division. Published 2020. Accessed January 27, 2026. 

https://med.stanford.edu/bmt/research/negrin-lab.html

ASH’s new president, Robert Negrin, explains key takeaways from the 67th meeting and sets the scene for ASH 2026. 


Hematology

Acne and Rosacea Treatment Updates for 2026, With Lawrence Eichenfield, MD

, a session was presented titled ‘Acne and Rosacea: Update 2026,’ featuring a discussion of challenging case scenarios and new insights into acne and rosacea treatment paradigms.

This session was presented by several speakers, 1 of whom was Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics at the UC San Diego School of Medicine. Eichenfield sat down with 

 to discuss takeaways from his acne and rosacea talk.

“There have been some new data that have come up,” Eichenfield stated. “There are questions that have remained in relation to isotretinoin in patients that come up all the time in practice. So I went through some of the data on them, especially the new data.”

Eichenfield noted recent, well-designed studies have come out suggesting isotretinoin does not adversely impact height among pediatric patients, addressing longstanding concerns some have expressed regarding premature epiphyseal closure. He also touched on evidence supporting cumulative dosing, rather than daily dose intensity, as the key element affecting the likelihood of relapse or need for repeat courses.

Additionally, Eichenfield spoke about updates related to hormonal therapies in acne. In particular, he spoke on the evolving guidelines related to oral contraceptive use in teenage adolescents with acne. Eichenfield pointed to forthcoming recommendations suggesting avoidance of oral contraceptives for acne treatment in individuals under the age of 16 years until they are at least 2 years post-menarche, given considerations around bone mineral density and pubertal development.

“That's a balance of the need for the treatment of acne with things like bone mineral density, where 90% of that happens up to the adolescent time period, as well as general pubertal health,” Eichenfield said. “And there are exceptions that are made if there are other conditions [such as] abnormal uterine bleeding, [polycystic ovary syndrome] syndrome that might give a reason to use OCPs for acne, plus other conditions.”

In the therapeutic realm, Eichenfield reinforced the continued central role of topical medications, highlighting strong study findings supporting the implementation of triple-combination topical treatments as highly effective monotherapies. These drugs, he noted, may be capable of diminishing one’s reliance on oral antibiotics. He addressed concerns about antibiotic resistance, highlighting data suggesting benzoyl peroxide–containing combinations mitigate this risk.

Eichenfield also spoke about newer hormonal approaches, noting certain topical agents can reduce sebum production. He reaffirmed isotretinoin’s role as a reliable “backstop” therapy capable of attaining near-universal clearance in those with severe acne.

For more news on recent trial data and insights into various dermatologic diseases, view 

The quotes used in this interview summary were edited for clarity.

Disclosures: Eichenfield previously reported receiving personal fees from Pfizer Inc; grant funding from AbbVie, Arcutis Biotherapeutics, Bausch + Lomb, Castle Biosciences, Dermavant Sciences Inc, Galderma SA, Pfizer Inc, Regeneron, and Sanofi SA and consulting for ASLAN Pharmaceuticals, AbbVie, Almirall, SA, Arcutis Biotherapeutics, Arena Pharmaceuticals Inc, Dermavant Sciences Inc, Galderma SA, Incyte Corporation, LEO Pharma A/S, Eli Lilly and Company, Ortho Dermatologics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi SA, and UCB; and serving on the board of directors of Forté Pharma.

Eichenfield L, Harper J, Baldwin H. Acne and Rosacea: Update 2026. Presented at: Maui Derm Hawaii 2026; January 25-29, 2026; Maui, Hawaii.

Picardo M, Eichenfield LF, Tan J. Acne and Rosacea. Dermatol Ther (Heidelb). 2017 Jan;7(Suppl 1):43-52. doi: 10.1007/s13555-016-0168-8. Epub 2017 Feb 1. PMID: 28150107; PMCID: PMC5289119.

This interview from the Maui Derm 2026 conference features Lawrence Eichenfield, MD, discussing takeaways from his talk ‘Acne and Rosacea: Update 2026.’

Acne

The HCPLive acne page is a resource for medical news and expert insights on dermatological disease. This page features expert-led coverage, articles, videos, and research on the therapies and development of treatments for chronic acne, and more.

Rosacea

On the HCPLive rosacea page, resources on the topics of medical news and expert insight into acne rosacea can be found. Content includes articles, interviews, videos, podcasts, and breaking news on the skin condition, and more.

David Golden, MD, clinical associate professor of medicine at Johns Hopkins University School of Medicine.

Anticipating The FDA Decision of Anaphylm for Anaphylaxis, With David Golden, MD

 date for epinephrine sublingual film (Anaphylm) in the treatment of 

 spoke with investigator David Golden, MD, clinical associate professor of medicine at the Johns Hopkins University School of Medicine, about how this novel formulation compares with epinephrine autoinjectors and the clinical relevance of the oral allergy syndrome challenge that supported the New Drug Application (NDA).

According to Golden, the median time to symptom resolution was 15.1 minutes with sublingual epinephrine film, versus 74 minutes without.

“We like the fact that Anaphylm works very rapidly, as fast as the auto injector,” Golden said.

He continued, saying that many doctors in hospitals or clinics administer epinephrine by manual injection rather than an auto-injector. However, manual epinephrine injections do not work as quickly as epinephrine sublingual film or autoinjectors. 

“That's one of the nice things that we can say about Anaphylm,” Golden added.

The NDA package included positive results from an oral allergy syndrome challenge, which found that allergic reaction symptoms resolved 2 minutes after epinephrine sublingual film administration.

 Epinephrine sublingual film, a polymer matrix-based epinephrine prodrug product candidate for anaphylaxis that weighs less than an ounce, showed promise in 11 independent clinical studies, encompassing approximately 967 administrations across 411 participants. At 10 minutes after epinephrine sublingual film administration, pediatric patients and adults had mean baseline-adjusted epinephrine concentrations over time of approximately 280 pg/mL and 330 pg/mL, respectively.

“I’m a big fan of having choices, and I don't think any 1 [treatment] is the right thing for everyone,” Golden said. “I have patients who will want to and should probably just continue to have auto injector prescriptions, and some people don't exactly love nasal spray, so they may want to try a sublingual film. Some people will find it more portable to carry the sublingual film. Again, it actually addresses a number of the problems that keep people from carrying it and using it and has some advantages that will appeal to many people, but I think there's a place for every one of those products.”

Brooks A. FDA Accepts Epinephrine (Anaphylm) Sublingual Film NDA for Type 1 Allergic Reactions. HCPLive. Published on June 19, 2025. Accessed on January 22, 2026.

 https://www.hcplive.com/view/fda-accepts-epinephrine-anaphylm-sublingual-film-nda-type-1-allergic-reactions

Derman C. Aquestive’s Anaphylm for Severe Allergic Reactions Shows Promise in Children. HCPLive Published on April 1, 2025. Accessed January 22, 2026.

 https://www.hcplive.com/view/aquestive-s-anaphylm-for-severe-allergic-reactions-shows-promise-in-children

As the January 31 PDUFA date approaches, Golden discusses that epinephrine sublingual film may deliver symptom relief as rapidly as autoinjectors, with added portability.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

MannKind Therapeutics has announced new starting dose recommendations for patients with type 1 diabetes switching from injected or insulin pump mealtime therapy.

FDA News

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

FDA Approves Updated Starting Dose Guidelines for Inhaled Insulin Powder (Afrezza)

Niels Lund, MSc is the vice president of Changing Diabetes at Novo Nordisk.

Lund highlights the value of preventive treatment in patients with prediabetes on the environment via reduced greenhouse gas emissions.

Type 2 Diabetes

Addressing Environmental and Cardiovascular Concerns in Diabetes Treatment, With Niels Lund, MSc

Frances Lee, MD, is an assistant professor of medicine in the division of liver diseases at Mount Sinai.

Explore the complex relationship between pruritus, fatigue, and bone health in patients with primary biliary cholangitis (PBC).

Key Symptoms of PBC- Fatigue, Pruritus, and Bone Health

Explore expert insights on primary biliary cholangitis, focusing on symptoms, treatment innovations, and emerging clinical data for effective patient management.

An Overview of PBC Pathophysiology, Severity, and Burden

Proteomic fragmentation may explain reduced allergenicity and point to a safer substrate for peanut oral immunotherapy compared with current options, new data suggests.


Food Allergy

How Autoclaving Alters Peanut Allergenicity, OIT Potential, With Casey Cohen, PhD

Learn how to set expectations, prevent flares, and choose among advanced topical therapies for pediatric atopic dermatitis and psoriasis.

Video Series

Proactive Flare Prevention and Practical Use of Advanced Pediatric Topicals

Daniel M. Siegel, MD, is a clinical professor of dermatology at SUNY Downstate Health Sciences University, New York, and is the former president and honorary member of the American Academy of Dermatology (AAD).

Siegel addressed additional points presented in his Maui Derm 2026 session, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

Tips on Billing Issues in Dermatology Practices, With Daniel Siegel, MD

In this interview, Siegel highlights key points presented in his Maui Derm 2026 talk, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

Discussing Billing Challenges in Dermatology, With Daniel Siegel, MD

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

An audio recap of the top 5 stories in healthcare news from the week of 01/18-01/24.

HCPLive 5 Stories in Under 5: Week of 01/18

Henry Lim, MD, is the senior vice president of academic programs at Henry Ford Health. He previously served as chair of the department of dermatology.

This interview with Lim highlights knowledge gaps examined by an international expert panel reviewing existing literature on dermatologic disease in skin of color.

Latest News

Icotrokinra Data at Maui Derm 2026 Reaffirm Efficacy in Psoriasis

Discussing GLP-1s, New Dermatology Therapies in 2026, With Neal Bhatia, MD

Looking Ahead to ASH’s 68th Meeting, With President Robert Negrin, MD

Acne and Rosacea Treatment Updates for 2026, With Lawrence Eichenfield, MD

Anticipating The FDA Decision of Anaphylm for Anaphylaxis, With David Golden, MD